Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation at the American Association for Cancer Research Annual Meeting

Author's Avatar
Mar 09, 2022

Poster presentations to highlight data from ongoing studies of the company’s lead Pan-RAF kinase inhibitor program, KIN-2787